TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Difference in burn-out syndrome measurements
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nausea and Vomiting Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Central sleep apnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improved Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Performance of BASET score for diagnosis of OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grading of the severity of OSAS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen uptake during peak exercise (Peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of serious ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of serious non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of histopathologically confirmed glomerular and tubulointerstitial diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in the Amplitude of Left Frontal Alpha Oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glycated haemoglobin (HbA1c) reduction ≥ 0.5%-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body weight reduction ≥ 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Core Temperature (°C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of High-Grade Squamous Intraepithelial Lesion (HSIL) and/or anal cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ADOS-2 SA change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial current intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final current intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhancement of Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of insomnia patients who remain in clinical study until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Accommodative amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Accommodative Facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Accommodative Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Pain Pressure Threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of stool butyrate producers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in Vitamin C plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Range of motion (ROM) with Goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: area under curve (AUC) of CKD-341, D956
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-341, D956
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of forced expiratory volume in the first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: NIPS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reoperation for infection recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Cure rate of Neisseria Gonorrhea cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of Landmarks Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants showing local vaccination reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants showing systemic vaccination reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of medically attended adverse events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of AEs leading to early participant withdrawal or permanent discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe desaturation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perioperative neurocognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Central Line-associated Bloodstream Infection (CLABSI) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Arrhythmia Biometric
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subject-Reported Symptom Biometric
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject Wellness Biometric
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subject Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Subject Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject Hospital Events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Subject Clinical Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: penetration cefazolin into synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: penetration cefazolin into bone tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: penetration clindamycin into bone tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of pain after SILAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with program - self-reported
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analogue Scoring (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bleeding on probing (BoP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve During the Dosing Interval τ (AUCτ) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Oral Clearance (CL) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Volume of Distribution (Vc) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life in mRCC patients receiving therapy as measured by FKSI-19
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in symptom burden in mRCC patients receiving therapy as measured by FKSI-19
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in quality of life in mRCC patients receiving therapy as measured by FACT-G
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in symptom burden in mRCC patients receiving therapy as measured by FACT-G
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in infarction volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental thickness threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cumulative incidence of catheter infection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with IFX Trough Levels ≥ 5 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seropositivity rate of the neutralizing antibody to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of the neutralizing antibody to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in vasoinotropic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-expiratory lung impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PUSH pressure ulcer scaling healing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of residents with recent HIV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in number of residents with PrEP prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in PrEP knowledge as measured by Five Point Initiative - Community Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Morphine Milliequivalent (MME) Use Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache Impact Scale (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Dizziness Handicap Inventory (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Motion Sickness Severity Scale (MSSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Simulator Sickness Survey (SHA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Informed choice about COVID-19 vaccination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety profile of the candidate vaccine ChAdOx1 RVF
Endpoint domain: Adverse events/effects
Primary endpoint: Early childhood asthma/persistent wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Patient-Reported Oral Mucositis Symptom Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative nausea and vomiting (PONV) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life 1y after ECMO insertion
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life 2y after ECMO insertion
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bacterial tracheobronchial colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Voiding pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mini Mental Status Examination (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effectiveness of H pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy of dietary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax after multiple dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24) after multiple dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician surveys that the software negatively affected patient care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinician surveys that the software positively affected patient care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinician surveys that ongoing use of the software poses risks that exceeds benefits
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Lamina Curved Plate in managing oroantral communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Patients who Possess Actionable Oncogenic Drivers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: User experience of thyroid cancer specific patient concerns inventory (PCI-TC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma oxidative stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebrospinal Fluid (CSF) oxidative stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of zetomipzomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of zetomipzomib
Endpoint domain: Adverse events/effects
Primary endpoint: Time to satisfactory sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repetitive Behaviors Scale-Revised (RBS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Injurious Behavior Questionnaire (SIB-Q)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-Reported Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient-Reported Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Reported Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Selective Control Assessment of the Lower Extremity (SCALE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BeCure Balance Assessment System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in truncal fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in maximal isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in maximal isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of a contextual structured report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of infants lost to follow-up for extreme prematurity
Endpoint domain: Mortality/survival
Primary endpoint: Safety of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Reaction time and latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voltage of N2 and Late Positive Potential (LPP) components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empathic pain rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in time in range (3.9-10 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve from Time 0 to the Time of Last Measurable Concentration (AUC0-last) of Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve from Time 0 Extrapolated to Infinity (AUC 0-inf) of Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of mucositis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores Using Numerical Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, Enjoyment and General Activity (PEG) Assessment Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diaphragm Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic orientation test sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic orientation test specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural response fidelity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain severity and interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total inspiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: evolution of respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Estimation of GFR pre-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Estimation of GFR three months post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Body appreciation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recruitment as Measured by Rates of Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention as Measured by Change in Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Helpfulness, Satisfaction, and Impact as Assessed by Self-Report Participant Feedback Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of Intervention Time as Measured by Number of Weeks to Complete Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Evaluation of POLE as a prognostic factor
Endpoint domain: Mortality/survival
Primary endpoint: Change of Barthel index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of Geriatric Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Lawton Instrumental Activities of Daily Living (IADL) Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Concentration of urinary 8-iso-prostaglandin F2a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of Flow-Mediated Dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local control rate at primary tumor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distance between pupil center and capsulorhexis center
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Health Questionnaire-8 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Complete Study Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number and characteristics of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neutralising antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vestibular network segregation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in THC use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Monthly Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of vessels in superficial retinal layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Density of vessels in deep retinal layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time to patient not requiring supplemental oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain measured by Algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured by Visual Analogic Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of planned walks completed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of infection rates in patients undergoing PCNL
Endpoint domain: Adverse events/effects
Primary endpoint: Goniometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pediatric Neuromuscular Recovery Scale (Peds NRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of Serious Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total proteins in grams
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes